Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. .
AKAMPIONJanuary 19, 2021 GMT
San Francisco, CA / Berlin, Germany – January 19, 2021 T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
“We welcome Tom and Camille to T-knife and look forward to their contributions as we continue to build our best-in-class T-cell receptor platform, advance our pipeline of innovative cell therapies, and transition to becoming a clinical-stage company in 2021,” stated Alexander Mayweg, Ph.D
Search jobs Rinri Therapeutics Appoints Terri Gaskell, PhD as Chief Technology Officer
Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announced the appointment of Dr. Terri Gaskell as its Chief Technology Officer (CTO) and member of the executive team. Dr. Gaskell brings over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
Terri joins from the UK Cell and Gene Therapy Catapult (CGTC) where she has worked for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGTC also included advising academics and small companies on the development of advanced therapies.
Rinri Therapeutics Appoints Terri Gaskell, PhD as Chief Technology Officer
SHEFFIELD, England, Dec. 17, 2020 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announced the appointment of Dr. Terri Gaskell as its Chief Technology Officer (CTO) and member of the executive team. Dr. Gaskell brings over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
Terri joins from the UK Cell and Gene Therapy Catapult (CGTC) where she has worked for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGTC also included advising academics and small companies on the development of advanced therapies.
December 10, 2020 healthcare
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.
Boehringer Ingelheim
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Friday, December 11, 2020 12:20PM IST (6:50AM GMT)
Ingelheim, Germany & Basel, Switzerland:
Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors
NBE-Therapeutics’pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform
NBE-Therapeutics’will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived